Gilead Sciences Inc Quick Ratio (GILD) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gilead Sciences Inc   (NASDAQ: GILD)

Gilead Sciences Inc 's Quick Ratio

GILD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




Within Biotechnology & Pharmaceuticals industry Gilead Sciences Inc booked the highest Quick Ratio than Gilead Sciences Inc in the third quarter 2026. While total ranking remained the same in the Q3 2026 compared to the second quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents GILD´s has?
What are GILD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GILD Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change -2.41 % 58.02 % -23.23 % 45.62 % 4.89 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ - - 0 0.01 0
GILD's Total Ranking # # # # #
Seq. Current Liabilities Change 8.91 % 16.29 % -19.78 % -3.94 % 76.34 %
Seq. Cash & cash equivalent Change - - -77.94 % 257.89 % -72.46 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Gilead Sciences Inc 's Current Liabilities $ 12,002 Millions Visit GILD's Balance sheet
Gilead Sciences Inc 's Cash & cash equivalent $ 0 Millions Visit GILD's Balance sheet
Source of GILD's Sales Visit GILD's Sales by Geography


Cumulative Gilead Sciences Inc 's Quick Ratio

GILD's Quick Ratio for the trailling 12 Months

GILD Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 11.54 % 13.92 % -5.59 % -0.47 % -7.61 %
Y / Y Cash & cash equivalent TTM Growth -5.68 % 47.83 % - - -92.54 %
Quick Ratio TTM 0 0 0 0 0
Total Ranking TTM # # # # #
Seq. Current Liabilities TTM Growth -0.66 % 9.98 % -6.6 % 9.32 % 1.46 %
Seq. Cash & cash equivalent TTM Growth -18.63 % -40.35 % 9.62 % 77.27 % 27.54 %

Quick ratio ranking by company, industry and sector >> Back to GILD Financial Strength Comparisons >> Go to Compare GILD Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in GILD's Current Liabilities to $12,002.00 millions, cumulative Quick Ratio